NVOS Novo Integrated Sciences Inc

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest reported): July 17, 2023

 

Novo Integrated Sciences, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada		001-40089		59-3691650
(State or other jurisdiction		(Commission		(IRS Employer
of Incorporation)		File Number)		Identification Number)

 

11120 NE 2nd Street, Suite 200, Bellevue, WA 98004

(Address of principal executive offices)

 

(206) 617-9797

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.)

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CF$ 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on which Registered
Common Stock		NVOS		Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On July 17, 2023, Novo Integrated Sciences, Inc. (“Novo”) issued a press release announcing its financial results for the fiscal quarter ended May 31, 2023. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information contained in the website is not a part of this Current Report on Form 8-K.

 

The information furnished pursuant to this Item 2.02, including the information contained in Exhibit 99.1, is “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.		Description
99.1		Press release issued by the registrant on July 17, 2023.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Novo Integrated Sciences, Inc.
Dated: July 17, 2023	By:	/s/ Robert Mattacchione
		Robert Mattacchione
		Chief Executive Officer

 

 

Exhibit 99.1

 

 

Novo Integrated Sciences Reports Fiscal Year 2023 Third Quarter Financial Results

 

BELLEVUE, Wash., July 17, 2023 - Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the third fiscal quarter ended May 31, 2023.

 

Robert Mattacchione, Novo’s CEO and Board Chairman, stated, “The Company remains committed to the commercialization of its proprietary product offerings and the expansion and delivery of its essential services and solutions of how non-catastrophic healthcare is delivered both now and in the future. During the fiscal year 2023 third quarter period, the Company announced the signing of agreements for an unsecured, non-dilutive 15-year debt instrument, with a principal sum of $70,000,000, which provides for the Company to receive net proceeds of approximately $55,000,000 after fees. In today’s environment of tight capital markets and expensive capital raises, this cash infusion is consequential and will provide the Company with the foundational capital and repayment terms required to support and accelerate the further implementation and growth of Novo’s three-pillar business model.”

 

Financial Highlights for the three month period ended May 31, 2023:

 

	●	Cash and cash equivalents were $464,011, total assets were $35.7 million, total liabilities were $9.5 million, and stockholders’ equity was $26.5 million.
	●	Revenues were $3,292,933, representing a decrease of $10,558,950, or 76%, from $13,851,883 for the same period in 2022. The decrease in revenue is principally due to the decrease in outsourced product sales and IoNovo Iodine. Acenzia’s and Terragenx’s revenue for the three months ended May 31, 2023 was $896,405 and $5,866, respectively. Revenue from our healthcare services decreased by 8% when comparing the revenue for the three months ended for the same period in 2022.
	●	Operating costs were $2,744,512, representing a decrease of $867,116, or 24%, from $3,611,628 for the same period in 2022. The decrease in operating costs was principally due to the decrease in overhead expenses and depreciation and amortization.
	●	Net loss attributed to the Company was $1,497,330, representing a decrease of $2,312,724, or 61%, from $3,810,054 for the same period in 2022. The decrease in net loss was principally due to the decrease in operating expenses.
	●	On March 21, 2023, the Company issued a $573,000 promissory note (12% per annum interest rate) and completed the related Securities Purchase Agreement with FirstFire Global Opportunities Fund, LLC (“FirstFire”) for gross proceeds of $515,700. The Company granted 5-year warrants with an exercise price of $0.25 per share and issued 955,000 restricted shares to FirstFire.
	●	On April 26, 2023, the Company entered into a securities purchase agreement with RC Consulting Group LLC in favor of SCP Tourbillion Monaco or registered assigns pursuant to which the Company issued an unsecured 15-year promissory note to the RC Noteholder (the “RC Note”) with a maturity date of April 26, 2038, in the principal sum of $70,000,000, which amount represents the $57,000,000 purchase price plus a yield (non-compounding) of 1.52% (zero coupon) per annum from April 26, 2023 until the same becomes due and payable as provided in the RC Note.
	●	Subsequent to the period ended May 31, 2023, on June 20, 2023, the Company issued a $445,000 promissory note (12% per annum interest rate) and completed the related Securities Purchase Agreement with Mast Hill Fund, L.P. for gross proceeds of $400,500. The Company granted 5-year warrants with an exercise price of $0.25 per share and issued 776,614 restricted shares to Mast Hill Fund, L.P.

 

 

About Novo Integrated Sciences, Inc.

 

Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.

 

We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.

 

The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:

 

	●	First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.
	●	Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home.
	●	Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.

 

Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient-first platforms.

 

For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com.

 

Twitter, LinkedIn, Facebook, Instagram, YouTube

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believe,” “intend,” “expect,” “anticipate,” “plan,” “potential,” “continue” or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in Novo’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond Novo’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

 

Contact

 

Chris David, COO-President

Novo Integrated Sciences, Inc.

chris.david@novointegrated.com

(888) 512-1195

 

 

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

As of May 31, 2023 (unaudited) and August 31, 2022

 

		May 31,				August 31,
		2023				2022
		(unaudited)
ASSETS
Current Assets:
Cash and cash equivalents		$	464,011			$	2,178,687
Accounts receivable, net			1,327,613				1,017,405
Inventory, net			938,940				879,033
Other receivables			1,046,080				1,085,335
Prepaid expenses and other current assets			221,414				571,335
Total current assets			3,998,058				5,731,795
Property and equipment, net			5,411,438				5,800,648
Intangible assets, net			16,696,363				18,840,619
Right-of-use assets, net			2,096,376				2,673,934
Goodwill			7,542,795				7,825,844
TOTAL ASSETS		$	35,745,030			$	40,872,840
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable		$	1,896,040			$	1,800,268
Accrued expenses			1,178,245				1,116,125
Accrued interest (including amounts to related parties)			350,831				454,189
Government loans and notes payable, current portion			312,672				-
Convertible notes payable, net of discount of $494,523			651,477				9,099,654
Contingent liability			57,933				534,595
Due to related parties			406,683				478,897
Debentures, related parties, current portion			912,025				-
Finance lease liability, current portion			13,814				8,890
Operating lease liability, current portion			428,951				582,088
Total current liabilities			6,208,671				14,074,706
Debentures, related parties, net of current portion			-				946,250
Government loans and notes payable, net of current portion			64,946				161,460
Finance lease liability, net of current portion			-				12,076
Operating lease liability, net of current portion			1,786,961				2,185,329
Deferred tax liability			1,393,168				1,445,448
TOTAL LIABILITIES			9,453,746				18,825,269
Commitments and contingencies			-				-
STOCKHOLDERS’ EQUITY
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at May 31, 2023 and August 31, 2022, respectively			-				-
Common stock; $0.001 par value; 499,000,000 shares authorized; 144,857,518 and 31,180,603 shares issued and outstanding at May 31, 2023 and August 31, 2022, respectively			144,857				31,181
Additional paid-in capital			89,249,590				66,056,824
Common stock to be issued (911,392 and 4,149,633 shares at May 31, 2023 and August 31, 2022, respectively)			1,217,293				9,474,807
Other comprehensive (loss) income			(172,526	)			560,836
Accumulated deficit			(63,872,587	)			(53,818,489	)
Total Novo Integrated Sciences, Inc. stockholders’ equity			26,566,627				22,305,159
Noncontrolling interest			(275,343	)			(257,588	)
Total stockholders’ equity			26,291,284				22,047,571
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	35,745,030			$	40,872,840

 

 

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

For the Three and Nine Months Ended May 31, 2023 and 2022 (unaudited)

 

		Three Months Ended								Nine Months Ended
		May 31,				May 31,				May 31,				May 31,
		2023				2022				2023				2022
Revenues		$	3,292,933			$	13,851,883			$	9,268,722			$	19,883,033
Cost of revenues			1,978,839				11,443,001				5,244,192				14,991,331
Gross profit			1,314,094				2,408,882				4,024,530				4,891,702
Operating expenses:
Selling expenses			1,877				9,802				9,916				36,340
General and administrative expenses			2,742,635				3,601,826				9,473,802				9,542,443
Total operating expenses			2,744,512				3,611,628				9,483,718				9,578,783
Loss from operations			(1,430,418	)			(1,202,746	)			(5,459,188	)			(4,687,081	)
Non-operating income (expense)
Interest income			62,397				8,355				6,762				25,233
Interest expense			(9,570	)			(513,398	)			(240,520	)			(1,808,310	)
Amortization of debt discount			(156,037	)			(2,133,890	)			(4,386,899	)			(3,654,752	)
Foreign currency transaction gain (loss)			48,333				97,654				12,652				(303,714	)
Total other expense			(54,877	)			(2,541,279	)			(4,608,005	)			(5,741,543	)
Loss before income taxes			(1,485,295	)			(3,744,025	)			(10,067,193	)			(10,428,624	)
Income tax expense			-				-				-				-
Net loss		$	(1,485,295	)		$	(3,744,025	)		$	(10,067,193	)		$	(10,428,624	)
Net loss attributed to noncontrolling interest			12,035				66,029				(13,095	)			(6,816	)
Net loss attributed to Novo Integrated Sciences, Inc.			(1,497,330	)			(3,810,054	)			(10,054,098	)			(10,421,808	)
Comprehensive loss:
Net loss			(1,485,295	)			(3,744,025	)			(10,067,193	)			(10,428,624	)
Foreign currency translation (loss) gain			(120,357	)			13,711				(738,022	)			24,916
Comprehensive loss:		$	(1,605,652	)		$	(3,730,314	)		$	(10,805,215	)		$	(10,403,708	)
Weighted average common shares outstanding – basic and diluted			143,600,541				29,817,999				85,832,252				28,498,414
Net loss per common share – basic and diluted		$	(0.01	)		$	(0.13	)		$	(0.12	)		$	(0.37	)

 

 

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the Three and Nine Months Ended May 31, 2023 and 2022 (unaudited)

 

		Common Stock								Additional Paid-in				Common Stock To				Other Comprehensive				Accumulated				Novo Stockholders’				Noncontrolling				Total
		Shares				Amount				Capital				Be Issued				Income				Deficit				Equity				Interest				Equity
Balance, August 31, 2022			31,180,603			$	31,181			$	66,056,824			$	9,474,807			$	560,836			$	(53,818,489	)		$	22,305,159			$	(257,588	)		$	22,047,571
Units issued for cash, net of offering costs			4,000,000				4,000				1,791,000				-				-				-				1,795,000				-				1,795,000
Issuance of common stock to be issued			36,222				36				92,330				(92,366	)			-				-				-				-				-
Cashless exercise of warrants			4,673,986				4,674				1,134,376				-				-				-				1,139,050				-				1,139,050
Fair value of stock options			-				-				60,887				-				-				-				60,887				-				60,887
Foreign currency translation loss			-				-				-				-				(417,008	)			-				(417,008	)			(3,974	)			(420,982	)
Net loss			-				-				-				-				-				(3,935,413	)			(3,935,413	)			(1,323	)			(3,936,736	)
Balance, November 30, 2022			39,890,811			$	39,891			$	69,135,417			$	9,382,441			$	143,828			$	(57,753,902	)		$	20,947,675			$	(262,885	)		$	20,684,790
Share issuance for convertible debt settlement			93,109,398				93,110				8,992,941				-				-				-				9,086,051				-				9,086,051
Cashless exercise of warrants			1,159,348				1,159				281,374				-				-				-				282,533				-				282,533
Exercise of warrants for cash			1,310,000				1,310				129,690				-				-				-				131,000				-				131,000
Issuance of common stock to be issued			3,202,019				3,201				8,161,947				(8,165,148	)			-				-				-				-				-
Shares issued with convertible notes			955,000				955				82,008				-				-				-				82,963				-				82,963
Value of warrants issued with convertible notes			-				-				86,327				-				-				-				86,327				-				86,327
Fair value of stock options			-				-				60,887				-				-				-				60,887				-				60,887
Extinguishment of derivative liability due to conversion			-				-				1,390,380				-				-				-				1,390,380				-				1,390,380
Foreign currency translation loss			-				-				-				-				(195,821	)			-				(195,821	)			(862	)			(196,683	)
Net loss			-				-				-				-				-				(4,621,355	)			(4,621,355	)			(23,807	)			(4,645,162	)
Balance, February 28, 2023			139,626,576			$	139,626			$	88,320,971			$	1,217,293			$	(51,993	)		$	(62,375,257	)		$	27,250,640			$	(287,554	)		$	26,963,086
Share issuance for convertible debt settlement			1,075,942				1,076				99,202				-				-				-				100,278				-				100,278
Exercise of warrants for cash			3,200,000				3,200				316,800				-				-				-				320,000				-				320,000
Shares issued with convertible notes			955,000				955				89,177				-				-				-				90,132				-				90,132
Value of warrants issued with convertible notes			-				-				93,811				-				-				-				93,811				-				93,811
Beneficial conversion feature upon issuance on convertible debt			-				-				66,068				-				-				-				66,068				-				66,068
Stock option expense			-				-				263,561				-				-				-				263,561				-				263,561
Foreign currency translation loss			-				-				-				-				(120,533	)			-				(120,533	)			176				(120,357	)
Net loss			-				-				-				-				-				(1,497,330	)			(1,497,330	)			12,035				(1,485,295	)
Balance, May 31, 2023			144,857,518			$	144,857			$	89,249,590			$	1,217,293			$	(172,526	)		$	(63,872,587	)		$	26,566,627			$	(275,343	)		$	26,291,284
Balance, August 31, 2021			26,610,144			$	26,610			$	54,579,396			$	9,236,607			$	991,077			$	(20,969,274	)		$	43,864,416			$	(60,261	)		$	43,804,155
Common stock for services			35,000				35				64,715				-				-				-				64,750				-				64,750
Common stock issued as collateral and held in escrow			2,000,000				2,000				(2,000	)			-				-				-				-				-				-
Common stock to be issued for purchase of Terragenx			-				-				-				983,925				-				-				983,925				97,311				1,081,236
Common stock to be issued for purchase of Mullin assets			-				-				-				188,925				-				-				188,925				-				188,925
Value of warrants issued with convertible notes			-				-				295,824				-				-				-				295,824				-				295,824
Fair value of stock options			-				-				154,135				-				-				-				154,135				-				154,135
Foreign currency translation loss			-				-				-				-				(103,533	)			-				(103,533	)			(855	)			(104,388	)
Net loss			-				-				-				-				-				(1,806,587	)			(1,806,587	)			(9,808	)			(1,816,395	)
Balance, November 30, 2021			28,645,144			$	28,645			$	55,092,070			$	10,409,457			$	887,544			$	(22,775,861	)		$	43,641,855			$	26,387			$	43,668,242
Common stock for services			240,000				240				297,760				-				-				-				298,000				-				298,000
Value of warrants issued with convertible notes			-				-				5,257,466				-				-				-				5,257,466				-				5,257,466
Fair value of stock options			-				-				44,427				-				-				-				44,427				-				44,427
Foreign currency translation gain			-				-				-				-				114,738				-				114,738				355				115,093
Net loss			-				-				-				-				-				(4,805,167	)			(4,805,167	)			(63,037	)			(4,868,204	)
Balance, February 28, 2022			28,885,144			$	28,885			$	60,691,723			$	10,409,457			$	1,002,282			$	(27,581,028	)		$	44,551,319			$	(36,295	)		$	44,515,024
Common stock issued for services			125,000				125				313,875				-				-				-				314,000				-				314,000
Share issuance for convertible debt settlement			623,929				624				1,247,225				-				-				-				1,247,849				-				1,247,849
Common stock issued for acquisition			800,000				800				1,703,200				-				-				-				1,704,000				-				1,704,000
Common stock to be issued for acquisitions			-				-				-				260,625				-				-				260,625				25,402				286,027
Issuance of common stock to be issued			225,000				225				573,525				(573,750	)			-				-				-				-				-
Fair value of stock options			-				-				91,330				-				-				-				91,330				-				91,330
Foreign currency translation gain			-				-				-				-				13,711				-				13,711				51				13,762
Net Loss																							(3,810,054	)			(3,810,054	)			66,029				(3,744,025	)
Balance, May 31, 2022			30,659,073			$	30,659			$	64,620,878			$	10,096,332			$	1,015,993			$	(31,391,082	)		$	44,372,780			$	55,187			$	44,427,967

 

 

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Nine Months Ended May 31, 2023 and 2022 (unaudited)

 

		Nine Months Ended
		May 31,				May 31,
		2023				2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$	(10,067,193	)		$	(10,428,624	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			1,718,388				2,349,434
Fair value of vested stock options			385,335				289,892
Common stock issued for services			-				676,750
Financing costs for debt extension			1,421,583				-
Operating lease expense			624,246				418,188
Amortization of debt discount			4,386,899				3,654,752
Foreign currency transaction (gain) loss			(12,652	)			303,714
Changes in operating assets and liabilities:
Accounts receivable			(308,907	)			(3,650,069	)
Inventory			(92,260	)			(263,539	)
Prepaid expenses and other current assets			333,724				(150,632	)
Accounts payable			154,542				117,056
Accrued expenses			104,004				(68,871	)
Accrued interest			(67,634	)			598,904
Operating lease liability			(594,618	)			(406,862	)
Net cash used in operating activities			(2,014,543	)			(6,559,907	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment			(18,870	)			(190,973	)
Cash acquired with acquisition			-				57,489
Payments received from other receivables			-				296,138
Net cash (used in) provided by investing activities			(18,870	)			162,654
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments to related parties			(56,649	)			(21,932	)
Repayments of finance leases			(6,435	)			(14,797	)
Proceeds from (repayments of) notes payable			222,000				(4,430,794	)
Proceeds from the sale of common stock, net of offering costs			1,795,000				-
Proceeds from exercise of warrants			451,000				-
Repayment of convertible notes			(3,033,888	)			-
Proceeds from issuance of convertible notes, net			925,306				15,270,000
Net cash provided by financing activities			296,334				10,802,477
Effect of exchange rate changes on cash and cash equivalents			22,403				(20,940	)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS			(1,714,676	)			4,384,284
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD			2,178,687				8,293,162
CASH AND CASH EQUIVALENTS, END OF PERIOD		$	464,011			$	12,677,446
CASH PAID FOR:
Interest		$	343,878			$	1,294,912
Income taxes		$	-			$	-
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for convertible debt settlement		$	9,186,329			$	1,247,849
Common stock to be issued for intangible assets		$	-			$	188,925
Common stock to be issued for acquisition		$	-			$	1,244,550
Common stock issued for acquisition		$	-			$	1,704,000
Beneficial conversion feature upon issuance of convertible notes		$	66,068			$	-
Debt discount recognized on derivative liability		$	1,390,380			$	-
Debt discount recognized on convertible note		$	639,993			$	-
Extinguishment of derivative liability due to conversion		$	1,390,380			$	-
Common stock issued with convertible notes		$	173,095			$	-
Warrants issued with convertible notes		$	180,138			$	-

 

v3.23.2

Cover	Jul. 17, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jul. 17, 2023
Entity File Number	001-40089
Entity Registrant Name	Novo Integrated Sciences, Inc.
Entity Central Index Key	0001138978
Entity Tax Identification Number	59-3691650
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	11120 NE 2nd Street
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Bellevue
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98004
City Area Code	(206)
Local Phone Number	617-9797
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	NVOS
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

---